Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

NCT ID: NCT02398604

Last Updated: 2021-07-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2019-03-31

Brief Summary

This study is intended to evaluate the safety and feasibility of intramyocardial injection of allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA) surgery for hypoplastic left heart syndrome (HLHS) pediatric patients.

Detailed Description

This is an open label study, intended as a safety and efficacy assessment prior to a full comparator study. In this Phase I study, cells administered will be delivered in 6-10 intramyocardial injections that will be tested in 20 patients and 10 patients will be controls with a total of 30 HLHS patients.

A total of 30 patients with HLHS will be enrolled in a staged enrollment process. In this open-labeled study, a maximum of 20 patients will eventually receive intramyocardial injection of the allogeneic mesenchymal stem cells and 10 control patients with no cell injection. The enrollment of the patients will occur in two stages groups: Group A and Group B. In Group A, 10 consecutive HLHS patients will be initially enrolled in the allogenic MSCs treatment arm to determine feasibility and safety. After 6 months of the last enrolled patient in Group A, all Group A patients will be assessed in order to determine whether it is feasible and safe, including the harvesting, processing, and administering of the allogeneic MSCs. Thereafter, Group B will start enrolling a total of 20 HLHS patients which will be randomized to the treatment and control arms in a 1:1 ratio, respectively, in order to have 10 allogeneic MSCs-treated patient and 10 control patients. At the completion of this Phase I clinical study, the total enrolled cohort will be 20 patients treated with allogeneic MSCs and 10 patients in the control arm.

Conditions

Hypoplastic Left Heart Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A - Allo-hMSCs

Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10\^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.

Group Type: EXPERIMENTAL

Allo-hMSCs

Intervention Type: DRUG

Allogeneic Human Mesenchymal Stem Cells

Group B

Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

Allo-hMSCs

Allogeneic Human Mesenchymal Stem Cells

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Other Intervention Names

stem cells; Allogeneic Human Mesenchymal Stem Cells; Placebo comparator

Eligibility Criteria

Inclusion Criteria

• Subjects with hypoplastic left heart syndrome (all types) requiring BDCPA surgery.

Exclusion Criteria

• Have HLHS and restrictive or intact atrial septum.
• Be undergoing the Norwood procedure that do not have HLHS.
• Have significant coronary artery sinusoids.
• Require mechanical circulatory support prior to surgery.
• Have an underlying evidence of arrhythmia requiring anti-arrhythmia therapy.
• Parent or guardian unwilling or unable to comply with necessary follow-up(s)
• Be serum positive for HIV, hepatitis BsAg (B Surface Antigen) or viremic hepatitis C.
• Be unsuitable for inclusion in the study, in the opinion of the investigator.
• Need for concomitant surgery for aortic coarctation or tricuspid valve repair.

• Maximum Eligible Age: 30 Days
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Longeveron Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anthony Oliva, MD

Role: PRINCIPAL_INVESTIGATOR

Longeveron Inc.

Locations

University of Maryland Medical Center

Baltimore, Maryland, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

Countries

United States

Related Links

http://isci.med.miami.edu

Interdisciplinary Stem Cell Institute

Other Identifiers

20140718

Identifier Type: -

Identifier Source: org_study_id